CLICK HERE for the Animal Health Investment 2020 website
Why Attend
Animal Health Investment Europe is a premier investment forum showcasing the most exciting investment opportunities in animal health and nutrition and connecting those businesses with financial investors and strategic corporate partners.
To complement our investment pitches, we host CEO-level discussions that address the trends and market dynamics of the animal health industry, across all species.
A key element of the investment forum is the full use of a our 1-on-1 private meeting platform, available to all attendees.
Going forward, as the industry experiences a shift towards the detection and prevention of disease, we are increasingly focused on presenting innovation in nutritional health, data analytics, sensors and diagnostics.
This year, for the first time, we will be categorising our presenting companies according to the level of investment they’re seeking, early, mid and late stage.
WORKSHOP DAY
**All workshops now fully booked**
A brilliant opportunity for Start-Up companies to get one-to-one advice from a host of Multinationals.
When: Monday 25th February
Where: etc. Venues, St Pauls, London
This is the same venue as the main two-day event
Workshops are free of charge to attend, and are available on a first-come, first-served basis.
We have spaces for 30 start-ups to attend - please note that only 1 representative from each company can apply at the moment due to limited places. If more people would like to attend please let Jessica know ([email protected]) and you will be added to a waiting list.
Please note that a workshop pass needs to be booked alongside attendance to the main two-day conference. It is not separately bookable.
Innovation Showcase
***FINALISTS ANNOUNCED**
Three Showcase Opportunities Available for 2019: A total of 24 start-ups, hand-picked by the Selection Committee, introduce themselves and their products/services on the main stage, in a quick-fire round of presentations.
Animal Health Innovation Showcase – 12 Companies presenting their technologies
Animal Nutrition Innovation Showcase – 8 Companies presenting their technologies
Human Health Innovation Showcase – 4 human health companies present their innovations
for possible applications in animal health
The Showcase will include Pre-Revenue and Pre-Series B companies seeking up to £2 million and Series B+ companies pitching for £2-10 million
Congratulations to all 24 Finalists, and thank you to the 60+ companies that applied to the Showcase.
Please click the "Innovation Showcase Finalists" PDF below to learn more about the most exciting innovations in animal health and nutrition from 2019...
Apply for Next Year's Showcase
Get ahead of the game and apply for the Innovation Showcase 2020.
The standard of applications this year was exceptional, and we had over 60 emerging companies submit their technologies to the Selection Committee.
Due to high demand we're now opening next year's Showcase early. You can already apply, free of charge, via our form here.
Start-ups are eligible for a discounted ticket to come and meet the investors face-to-face at this year's meeting in February - book here
Highlights from the Series
Selection Committee
Charles Hoare
Matthias Hofer
Julia Stephanus
Michael Hemprich
Maarten Goossens
Martijn Adorf
Greg Sunvold
Jarne Ellenholm
Paul Dick
Isaac Fraynd
Advisory Board
Clinton Lewis
Joachim Hasenmaier
Dirk Ehle
George Gunn
Linda Rhodes
Aaron Schacht
Alan Mackay
Dr. James Lloyd
Sébastien Huron
Jean Deleforge
ACCOMMODATION
Grange St. Paul’s Hotel
10 Godliman Street, London, EC4V 5AJ (0.6 miles from 200 Aldersgate)
To book a room please email: [email protected]
Book online: http://www.grangehotels.com/business/kisaco-allocation/
Or call Reservations: + 44 (0) 207 074 1000
Sunday 24th Feb £99.00 includes VAT & Continental breakfast
Monday 25th Feb £229.00 includes VAT & Continental breakfast
Tuesday 26th Feb £279.00 includes VAT & Continental breakfast
Quote Group ID 240219B when booking
Please book by 27 January 2019
Thistle City Barbican Hotel
120 Central St, London EC1V 8DS (0.8 miles from 200 Aldersgate)
Rate per night: £135.00 including VAT & English breakfast
To book a room please call reservations: +44 (0) 800 330 8002 (Option 1)
Email: [email protected]
Quote block code GA1L240219 when booking
Please book by 27 January 2019
Crowne Plaza London The City
19 New Bridge St, London EC4V 6DB (0.8 mile from 200 Aldersgate)
Sunday 24th February £209 inc VAT and English breakfast
Mon 25th & Tues 26th February £289 inc VAT & English breakfast
Book online: here
Call reservations + 44 (0) 207 438 8040
email: [email protected]
Quote ‘allocation code ‘GA2’ when booking
Please book by 13 January 2019
Holiday Inn London Whitechapel
5 Cavell Street, London, E1 2BP (1.9 miles from 200 Aldersgate)
Sunday 24th Feb £99 inc VAT and full English breakfast
Monday 25th Feb £129 inc VAT & full English breakfast
Tuesday 26th Feb £189 inc VAT and full English Breakfast
Book online at: GA1 Kisaco
Call reservations +44(0) 207 791 9013
Quote block code ‘GA3’ when booking
Please book by 27 January 2019
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
- Please note that a £49 processing fee will apply to any invoices requested.
- Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
- All Prices are in GBP
- All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
- No discounts or offers can be combined.
- Please view our Cancellation Policy.
- Emerging Companies are defined as early to mid-stage animal health pharmaceutical or biotech companies that are actively seeking financial investment or product licensing/acquisition. They must be engaged with this company on a full time basis. Those offering consultancy or market intelligence services do not qualify for this rate.
- Please Note: No additional discounts are available on ‘Emerging Company’ pricing.
The Speakers
Lord Alexander John Trees, Baron Trees
Lord Trees qualified as a veterinarian in 1969 and has worked in general practice, industry and, for most of his career, academia. In 1980 he was appointed Lecturer in Veterinary Parasitology at the University of Liverpool based in the Liverpool School of Tropical Medicine. He was Professor of Veterinary Parasitology from 1994 and Dean of the Faculty of Veterinary Science from 2001 – 2008. His research embraced livestock disease in both temperate and tropical environments, including a strong interest in One Health and parasitic infections as models of human tropical disease. He retired from the University in 2011.
He was President of the Royal College of Veterinary Surgeons in 2009-2010, and is currently Chair of the Moredun Research Institute Board, Veterinary Editor in Chief of the Vet Record and In Practice, and an Honorary Fellow of the Royal Society of Edinburgh.
In 2012 he was appointed a Crossbench Peer in the House of Lords Commission and is only the second veterinary surgeon to be appointed. There he has served on the EU Select Committee and its Sub-Committee on Energy and Environment (which included agriculture) and has participated in the production of 20 House of Lords Select Committee Reports published 2015-2017, many on the consequences of Brexit including on Brexit: Agriculture and Brexit: Farm Animal Welfare.
Joachim Hasenmaier
Joachim Hasenmaier, born 1960 in Vaihingen/Enz, Germany, DVM., is Member of the Board of Managing Directors of C.H. Boehringer Sohn AG & Co. KG since October 1, 2012, responsible for the Corporate Board Division Consumer Health Care and Animal Health. His nationality is German.
He received a veterinary medical degree (DVM) in 1986 from Ludwig-Maximilians-University, Munich, where he entered into a microbiological research program until 1989 receiving his Doktor med. vet. (PhD) degree. He completed his education with a Master in Management from Kellogg Business School, Chicago, USA in 1991. Prior to joining BI he worked in various positions for various international companies in Germany, Japan, Mexico and Brazil.
In 2002 he joined Boehringer Ingeheim as Corporate Senior Vice President for Boehringer Ingelheim Animal Health. In 2011 he took over the regional responsibilty for Prescription Medicine in NECAR (UK/Ireland, Nordics, Benelux, Canada, Australia/New Zealand). He held this position until he became Member of the Board of Managing Directors at C.H. Boehringer Sohn AG & Co. KG in October 2012.
Daan Luining
Daan Luining is Meatable’s CTO and scientific mastermind. Daan lives and breathes clean meat and has been involved since the earliest stages, having worked on the first lab grown hamburger in 2013. After that, Daan expanded his knowledge on the field at New Harvest, an NGO that funds academic research in cell-based meat.
Barney Kay
Clinton Lewis
Clint Lewis is executive vice president and president of International Operations at Zoetis. In this role, he oversees the management of the livestock and companion animal business markets outside the United States.
Mr. Lewis previously served as president, U.S. Operations at Zoetis and in the Pfizer Animal Health organization. He joined Pfizer Animal Health in 2007.
Mr. Lewis joined Pfizer in 1988 as a sales representative in Long Island, N.Y., and has held positions of increasing responsibility in several areas across various commercial operations dedicated to human health prior to joining animal health, including vice president and general manager of Pfizer’s U.S. Anti-Infectives/HIV business unit.
In 2011, Mr. Lewis was elected chairman of the Animal Health Institute (AHI) for the 2011-12 term. A member of AHI since 2007, Mr. Lewis previously served as AHI vice chair for the 2009-2010 term. AHI is the trade association for the animal health industry in the U.S. advocating on various issues important to the industry, including efficient and effective regulatory and approval processes by the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), and the Environmental Protection Agency (EPA).
Mr. Lewis holds a bachelor’s degree in biology from Fairfield University and a Master of Business Administration in marketing from Fairleigh Dickinson University.
Jeff Simmons
Simon Innes
Simon was appointed as Chief Executive in January 2004. Prior to this he was Chief Executive of Vision Express from 2000 to 2004, over which time he built the business up to £220m turnover and 205 practices, and reversed a loss-making position to create one of the most profitable corporate optical operators in the UK. The growth strategy that was successful at Vision Express is now being implemented in the veterinary industry by CVS.
Prior to Vision Express, Simon was on the board of Hamleys PLC as Operations Director and gained 10 years’ management experience at Marks & Spencer. He also served seven years in the British Army, achieving the rank of Captain in the Royal Engineers.
David Hunt
Greg Sunvold
Kathy V. Turner
Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.
Mathieu Castex
Linda Rhodes
Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.
Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.
Davide Rossi
James Andrews
Aaron Schacht
Mr. Aaron Schacht is currently the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Health. Prior to this, Mr. Aaron Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.
Berwyn Clarke
Joseph Harvey
Brian Topper
Matt Dobbs
Mark Heffernan
Prior to joining Stonehaven Incubate, Dr Heffernan was the founding CEO and director at Nexvet Biopharma plc, a company pioneering the development of monoclonal antibodies in animal health. Since co-founding Nexvet in 2010, he raised more than US$80 million in capital, including the company’s NASDAQ public listing in 2015. Nexvet Biopharma was acquired by the world’s largest animal health company, Zoetis, in 2017.
Prior to Nexvet, he was also co-founder of an Irish biotechnology company, Opsona Therapeutics, focused on therapeutics for human inflammatory diseases where he raised US$50 million to commercialise research from Trinity College Dublin. Through his career, he has worked in research and business development in the USA, Asia Pacific and Europe.
Maarten Goossens
Maarten is a Co-founder and Principal at Anterra Capital. He began his investing career as an Analyst within the Rabo Ventures team in 2009 and was primarily responsible for deal sourcing and execution, and portfolio management.
Prior to joining Rabo Ventures, Maarten was an Analyst in the Rabobank-Rothschild M&A joint venture in London, where he focused on transactions in Food & Agriculture.
Maarten holds a Masters of Business Administration from the Free University of Amsterdam, and has studied at the London School of Economics.
Laëtitia Gerbe
Robin Hargreaves
Peter McCarthy
Mr. McCarthy is now in his 7th year at Henry Schein, Inc. He is currently the Company's President, Global Animal Health Group, as well as a member of Henry Schein's Executive Management Committee.
Mr. McCarthy oversees Henry Schein's animal health business, which spans 24 countries including the United States, Australia, New Zealand, Canada, China, Malaysia, Brazil and 17 countries in Europe.
Before assuming his current position, Mr. McCarthy held key roles at Henry Schein with increasing responsibilities, including President, Henry Schein Animal Health, Europe, and President, Henry Schein Animal Health, International.
Prior to joining Henry Schein, Mr. McCarthy worked at Schering-Plough Animal Health (now Merck Animal Health), serving as Senior Director, Global Operations and General Manager, China. Mr. McCarthy also worked at Wyeth/American Cyanamid for 14 years, helping to grow the human pharmaceutical business.
Mr. McCarthy holds a degree in Applied Biology from the University of Hertfordshire in the U.K., and previously has served as a Member of the Board of the International Federation for Animal Health Europe, and the International Association Executive Animal Health Study Center, CEESA, based in Belgium. Mr. McCarthy is also a graduate and member of the Chartered Institute of Marketing (CIM), which is located in the U.K.
Alan Mackay
Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.
Marcel Lacaze
Marcel joined Permira as a Principal in 2014 and focuses on the healthcare sector. Prior to joining Permira, Marcel worked for Novartis, leading the M&A activities for Novartis Consumer Health, Vaccines & Diagnostics. Before that, he spent eight years in investment banking working for Lazard and Merrill Lynch. Marcel holds degrees in Business Administration, Economics and languages from the University of Passau, Germany, as well as Bejing Yuyan Xueyan, China.
Cindy Barnes
Roy Stein
Antione Hubert
James Millar
Simon Doherty
Simon Doherty, president of the British Veterinary Association (BVA) is a veterinary consultant and senior lecturer at Queen’s University Belfast.
With two decades of experience in veterinary practice, industry and academia, Simon is well positioned to represent the varied veterinary roles and diversity of BVA’s 18,000+ members.
For three years, Simon was the Animal Sciences & Aquaculture specialist for the Department for International Trade. Last year, he was appointed a GlobalScot in the animal health & aquaculture sector by the Office of the First Minister in Scotland.
Simon is a past president of the North of Ireland Veterinary Association and of the Northern Ireland Branch of BVA. He currently chairs the UK One Health Coordination Group and is one of two BVA representatives at the Federation of Veterinarians in Europe (FVE). He also chairs the FVE FishMedPlus Coalition.
A STEM Ambassador, he is also actively involved in the provision of veterinary careers advice, regularly mentoring applicants to veterinary school. He is also an ambassador for the livestock development charity, Send a Cow, and a trustee of the Animal Welfare Foundation.
Follow Simon on Twitter:
@simondocvet @britishvets
#OneVeterinaryCommunity #AStrongVoiceForVets
David Perin
Jean-Louis Hunault
My professional activity began as a lecturer in public law at the University of Paris 2 and Paris V and in 1988 as legal counsel and then director of economic and legal affairs of the Union of Plant Protection Industries - UIPP. Graduated from HEC's Executive MBA in 1993 I created and managed 2 companies in the environment and direct marketing sector. In 1996, I joined the veterinary medicine and diagnostics industry union - SIMV as secretary general. I was elected Chairman of the SIMV Board 5 times. My last term will cover the period 2018-2021.
I exercise different mandates: administrator of the national agency of health safety of the food, environment and work - ANSES, substitute member of the National Council of the higher education and the research (CNESER), secretary of the French network for animal health - RFSA.
At the European level, I am member of the Board of the European Federation of Animal Health - Animal Health Europe.
At the global level, I held the position of Director Europe for a five-year term on the Board of Directors of our World Federation (Heath for Animals).
I am the Secretary General of the World Veterinary Diagnostics Industry Federation - DiagnosticsforAnimals - an organization I created in 2007.
Kay O'Donnell
Eric Garcia
Mike Seely
Anthony Roberts
Anthony is responsible for the delivery of the strategic ambition to become a Royal College with leadership and innovation at its heart.
Leadership work includes the implementation of a programme to support the next generation of veterinary leaders and develop leadership opportunities across the veterinary professions, and the completion of the RCVS governance review to ensure that we are an effective and efficient organisation, better able to lead the profession and serve the needs of the public.
Innovation incorporates the development of initiatives to ensure the veterinary professions are at the centre of innovation in the animal health sector, to position the professions as open to innovation, and to ensure the RCVS serves to foster innovation whilst continuing to protect animal health and welfare.
Anthony also leads the development and delivery of a programme of work to prepare the College and the profession for the impact of Brexit and the implementation of evidence-based measures to drive the transition to a supportive ‘learning-culture’ in the veterinary professions.
Anthony has worked at the RCVS for seven years and has been responsible for delivering key projects such as the First Rate Regulator Initiative (2012/13) and the launch of the new Practice Standards Scheme (2015). Prior to joining the RCVS Anthony worked in public affairs and media relations at the British Plastics Federation, the trade association for the UK plastics industry.
Anthony holds an MBA from Warwick Business School (2016), an MA (Hons) in Philosophy and Politics from the University of Edinburgh (2004) and the CIPR Diploma in Public Relations (2009).
Marie Paul-Lachaud
Since 2013, Dr. Marie-Paul Lachaud has served as Head of Program Management Europe at Aratana Therapeutics Inc.. Her responsibilities include coordinating the process leading to regulatory approval by the European Medicines Agency for Aratana’s products, most recently GALLIPRANT.
Since 2009, Dr. Lachaud has also provided services to the veterinary pharmaceutical industry as an experienced independent consultant, with a specific focus on international clinical development and registration of animal drugs.
From 2000 to 2008, Dr. Lachaud was the European Animal Health Director at ICON Clinical Research in Paris, France. In 1990, she co-founded PROTOCOLE, the first European veterinary consultancy and Contract Research Organization dedicated to veterinary drug clinical development and regulatory affairs, which was acquired by ICON in 2000.
Throughout her career, Dr. Lachaud has been involved in transitioning human drugs to meet unmet needs in veterinary medicine. Her work has resulted in significant companion animal health product approvals in Europe and the United-States in a number of innovative therapeutic areas, including reproduction, atopic dermatitis, chronic heart failure, wound healing, chronic kidney disease, acute and chronic pain, obesity, inappetence, cancer, cognitive dysfunction and anxiety-related disorders.
She received her veterinary degree from Alfort National Veterinary School in Paris and her doctorate in veterinary medicine from the University of Paris, France.
Duncan Lascelles
B. Duncan X. Lascelles
BSc, BVSC, PhD, MRCVS, CertVA, DSAS(ST), Diplomate ECVS, Diplomate ACVS
Professor of Surgery and Pain Management
Director, Comparative Pain Research and Education Centre
Translational Research in Pain Programme,
North Carolina State University College of Veterinary Medicine, Raleigh, NC, 27606, USA
After graduating from the veterinary program at the University of Bristol, U.K., with honors, in 1991 Dr. Lascelles completed a PhD in aspects of pre-emptive/perioperative analgesia at the University of Bristol. After an internship there, he completed his surgical residency at the University of Cambridge, U.K. He moved to Colorado for the Fellowship in Oncological Surgery at Colorado State University, then a period of post-doctoral research in feline pain and analgesia at the University of Florida, and is currently Professor in Small Animal Surgery and Pain Management at North Carolina State University. He is board-certified in small animal surgery by the Royal College of Veterinary Surgeons, the European College of Veterinary Surgeons, and the American College of Veterinary Surgeons.
He is director of the Comparative Pain Research and Education Centre (CPREC). His research program (Translational Research in Pain [TRiP]) is dedicated to answering critical questions about pain control and pain mechanisms through high quality, innovative research. His career has been focused on developing algometry methods (methods to measure pain) in spontaneous disease animal models (pets with naturally occurring disease), and probing tissues from well-phenotyped animals with spontaneous disease to understand the neurobiology, with a strong translational focus. The aim of his research is to improve pain control in companion animals, and facilitate analgesic development in human medicine. He has authored over 180 peer reviewed research papers and reviews and 190 research abstracts, as well as over 30 book chapters.
He has worked closely with industry partners in both animal and human health, helping to re-define the relationship between industry and academia. Through reviews and invited presentations he advocates for the use of spontaneous disease in animals to inform human therapeutic development. Recently, he organized a meeting of industry, academia, regulatory authorities (FDA) and the NIH to discuss measurement of chronic pain in companion animals and the application to human pain research (www.PAW2017.com), and is planning PAW2019. He is completing a year-long integrated sabbatical within a pain therapeutic company (Centrexion Therapeutics) that develops novel therapeutics for both humans and animals. He provides consulting services related to pain therapeutic development across all stages of animal therapeutic development, and for pre-clinical and Phase I stages of human therapeutic development.
Through his work in academia and industry, he contributes to and facilitates the development of novel pain therapeutics for companion animals, and advocates for the use of spontaneous disease in pets to inform human pain therapeutic development.
Dirk Ehle
Dr. Dirk Ehle has been a member of the Bayer HealthCare Executive Committee and responsible for the Animal Health Division since May 1, 2012.
Dirk Ehle was born on May 26, 1969, in Cologne, Germany. He studied law at the universities of Freiburg, Aix-en-Provence (France), Wurzburg, and New York (USA).
After three years in law firms, Dirk Ehle started his career at Bayer in 2001 in the Law Department of Bayer HealthCare. In 2006, Ehle transferred to Bayer AG’s Corporate Office where he worked as Executive Assistant to the Chairman of the Board of Management. He was also in charge of Corporate Policy & Advocacy as of 2008. In 2010, Ehle was appointed Senior Bayer Representative for Central Eastern Europe and Bayer HealthCare Representative for Poland.
Dirk Ehle is married with three children.
Bénédicte Flambard
Bénédicte Flambard currently is heading the Business Unit of Live Therapeutics & Nutraceuticals at Boehringer Ingelheim. She leads the creation of a new business area at the interface of Therapeutic Nutrition and Health, combining novel microbial based bio-therapeutic and diagnostic approaches.
Previously, Bénédicte worked for Merial and for Chr. Hansen, the world Leader in Microbial Solutions. She hold several Vice President positions across commercial and innovation areas, dedicated to Health Supplements for Pharma, OTC, Infant Formula as well as Agricultural Industries (Animal Feed & Plant). While growing core businesses, she was seeding and developing Growth Opportunities into Start Up businesses- one focusing exclusively on Microbiome.
She holds several trustee positions as Board Member at the Quadram Institute, as well as diverse Advisory roles to organizations in the sectors of consumer goods, pharmaceuticals and technology.
Bénédicte holds a Master of Administration, with specialties in business models in emerging economies from the University of Bath in the U.K.; a PhD in Molecular Genetics and Microbial Physiology from INRA (National Institute of Agronomic) in France; and a Master in Corporate Entrepreneurial Leadership from the Centre for Technology Economics & Management in Denmark.
Jennifer Filbey
Jolyon Martin
Joost Matthijssen
Justine Conway
Kenneth Lee
For the past two decades, Ken has worked with global leaders of the food and consumer care industry to leverage early stage science into game-changing innovations. He cut his teeth at L’Oréal, where he established a process enabling the company to take advantage of opportunities that arise in a fast-changing world. Ken led the Strategic Foresight function for the L’Oréal Group and undertook missions in Brazil, China, India, Israel, Japan and the US.
Ken moved to Singapore in 2013 to join the Agency for Science, Technology & Research (A*STAR), where he played a pivotal role in architecting the strategy to establish Singapore as a leading science and innovation hub for the food, nutrition and consumer care industry. Ken and his team were successful in securing more than S$170 million in funding from the Singapore government to support new R&D programmes that address the key industry drivers of efficacy, safety and sustainability. These programmes helped to attract new investments by some of the largest companies in food and consumer care (CAGR +31%); and created an ecosystem comprising global brand owners, ingredients innovators and start-up companies.
Ken holds a PhD from the University of Edinburgh, and undertook doctoral and post-doctoral research in stem cells. He has been a member of New Protein Capital’s Investment Committee since 2016, stepping down in August 2018 when he was appointed Senior Partner.
Nick Hill
Starting out as a physicist, he studied at Oxford University before switching to Cambridge University for a PhD in quantum physics of semiconductor devices.
After completion of his PhD, Nick worked for Cambridge company NXT, he helped develop its revolutionary audio technology, which over the years proved an exceptional training ground in many areas including research management, product development, patents, and IP protection.
During this time, his passion for invention and entrepreneurship saw his career path take a different trajectory. Bitten by the start-up bug, he went on to develop an innovative cat flap for his cat (Flipper) – releasing the Microchip Cat Flap in 2008.
Following the global success of the Sure Petcare range of microchip reading pet door and feeders, Sure Petcare became part of the Antelliq family in 2015. Nick now heads the Antelliq consumer pet division. Where combining the of using a pet’s microchip and connected products is enabling the future of intelligent pet care.
Sébastien Huron
Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.
Sébastien Lafon
Bruno Cluzel
Bruno Cluzel is Executive Director, International Operations, Diagnostics Customer Care for Zoetis. In this role, he is responsible to define guidelines for customer and technical support services delivered in the markets; deliver elevated technical support and instrument repair; provide guidance to the Diagnostic Application Specialists in-market technical support; and develop and help deliver training curriculum, materials and sessions.
Bruno has extensive experience working within the animal health care sector. Through his career, Bruno has held various roles working across a number of different functions and regions.
With a passion for animal health, Bruno holds a diploma of Veterinary Medicine and started his career as a Practitioner specialized in Production Animal with a focus on Avian Medicine. After 15 years in this role, he joined Merial where he had different roles across Europe Africa and Middle East: technical, marketing and business lead. He joined Pfizer Animal Health in 2011 to help entering the Diagnostics. In his current role, he is building Customer Care capabilities as Zoetis expands around the Globe.
Rachel Dean
Dr Rachel Dean BVMS PhD MSc(EBHC) DSAM(fel) SFHEA MRCVS is a graduate from University of Glasgow and has worked in mixed, dairy and small animal general practice. She is holds the RCVS diploma in feline medicine, has a PhD in epidemiology and an MSc in Evidence-based Healthcare. She was the founding director of the Centre for Evidence-based Veterinary Medicine and a Clinical Associate Professor in Feline Medicine at the University of Nottingham from 2009-2018. Rachel is currently the Director of Clinical Research and Excellence in Practice and co-chairs the clinical board for VetPartners. Rachel is responsible for supporting the clinical teams to constantly improve standards of care across the business and encourage clinical leadership through research, innovation and professional development.
Patrick Charlton
Patrick Charlton is vice president at Alltech and CEO of Coppens International, a specialist aquaculture feeds company, which was acquired by Alltech in 2016.
Before joining Coppens International, Charlton oversaw the activity of 32 Alltech offices across the European region. He graduated from the University of Nottingham and joined Alltech U.K. in 1991, becoming the technical manager in 1995.
In 1998, Charlton moved to Cape Town, South Africa, to become technical director for Alltech’s Africa and Middle East region, working with customers in Saudi Arabia, Egypt, Israel, Iran, South Africa, Kenya, Ghana and Zimbabwe. Charlton took on the role of general manager of Alltech Canada in 2000, working with customers, consultants and researchers across Canada. In 2005, he was promoted to global Bioplex® manager, responsible for all activities relating to the Bioplex series of organic minerals.
Charlton currently lives in the U.K. and received a master’s degree in fermentation and distilling from Heriot-Watt University in 2006.
This year we will have a special opening welcome from Lord Alexander John Trees, Baron Trees, Professor of Veterinary Parasitology and a Crossbench member of the House of Lords.
Lord Trees qualified as a veterinarian in 1969 and has worked in general practice, industry and, for most of his career, academia. As Dean of the Faculty of Veterinary Science at the University of Liverpool his research embraced livestock disease in both temperate and tropical environments, including a strong interest in One Health and parasitic infections as models of human tropical disease.
Lord Trees was President of the Royal College of Veterinary Surgeons in 2009-2010, and is currently Chair of the Moredun Research Institute Board, Veterinary Editor in Chief of the Vet Record and In Practice, and an Honorary Fellow of the Royal Society of Edinburgh.
In 2012 he was appointed a Crossbench Peer in the House of Lords Commission and is only the second veterinary surgeon to be appointed.
The Agenda
You can download our latest agenda here.
Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.
Alongside our renowned animal health track, which brings you a showcase of the most exciting investment opportunities and novel technologies in animal health, brand new for 2019 will be a dedicated nutrition investment forum, a veterinary practice track and also a human health partnerintg track.
Download the agenda to learn more...
Download the Agenda
Partners
Animal Health Investment Europe is supported by the most influential bodies across the Animal Health, Nutrition and Veterinary industries.
Be one of them, communicate about the event to your network, spread the word and become a Supporter of the Animal Health Investment series.
Headline Partner
Zoetis
Website: http://www.zoetis.com
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees.
For more information, visit www.zoetis.com.
Associate Partners
Argenta
Website: http://www.argentaglobal.com
Argenta Limited, founded in 2006, is the world’s only combined contract research organization (CRO) and contract manufacturing organization (CMO) specializing in animal health. With accredited operations and facilities across New Zealand, the United States and Scotland, Argenta is fully equipped to offer a full range of products and services - from access to innovative intellectual property, formulations research and development (R&D), analytical methods development, clinical trial management through to pilot- technical transfer and commercial-scale manufacturing - to the global animal health industry. Argenta’s 400+ global team develops and exports products and services to over 40 countries.
A privately-owned company headquartered in Auckland, New Zealand, Argenta brings innovation, R&D and manufacturing expertise together in one global company. This makes it ideally placed to accommodate unique product requirements no matter the scale or complexity. Argenta’s facilities in New Zealand, the United States (Iowa, Kansas and New Jersey) and Europe (Scotland) enable the achievement of significant efficiencies in product development and technology transfer, and to provide market intelligence and in-depth knowledge of market preferences in different countries as required.
Argenta is honoured to work with a vast range of clients globally - from small and medium-sized enterprises (SMEs) to some of the largest industry players. Argenta has the R&D capabilities and manufacturing scale to service the requirements of the largest multinationals, while, at the other end of the spectrum, Argenta works with startups and small companies with great ideas to help them find solutions and bring their ideas to fruition.
For more information, please visit www.argentaglobal.com.
Bayer
Website: http://www.bayer.com
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.
Boehringer Ingelheim
Website: http://www.boehringer-ingelheim.com
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates presently with a total of some 50,000 employees worldwide. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.
For more information, please visit www.Boehringer-Ingleheim.com
Elanco
Website: http://www.elanco.com
Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for more than 6,500 employees worldwide. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. We understand the powerful role healthy animals play in making lives better. We support the physical, emotional and social well-being of people thru a balanced diet rich in protein and the companionship of a pet. And, we preserve the health of the planet by helping farmers raise animals more efficiently. Since our start at Eli Lilly and Company in 1954, Elanco has been working to empower our customers—from veterinarians to food producers to all those concerned with animal health—to address these global challenges, and advance a vision of food and companionship enriching life. Visit us at Elanco.com and EnoughMovement.com.
GHO Capital
Website: http://ghocapital.com
Global Healthcare Opportunities, or GHO Capital Partners LLP, was founded in 2014 as a specialist healthcare private equity firm based in London. GHO Capital works with ambitious management teams of profitable businesses that have the potential to deliver a combination of double-digit top line growth, significant efficiency gains and international expansion. The Firm’s 2015 vintage fund – GHO Capital Fund I LP – has been raised to seize the highly attractive and underpenetrated European market opportunity. GHO Capital has a powerful combination of transaction, investment and industry skills which sets the Firm apart from traditional private equity firms. For further information, please visit www.ghocapital.com.
IDEXX BioAnalytics
Website: http://www.idexbioanalytics.eu
IDEXX BioAnalytics is your strategic partner for reliable, reproducible results whilst accelerating your research through innovative technologies, logistics support and scientific expertise, so you can confidently improve the health and welfare of people and animals.
IDEXX BioAnalytics is a division of IDEXX Laboratories which was founded in 1983.
In the last 15 years, IDEXX BioAnalytics scientists have been innovation leaders in laboratory animal diagnostics, publishing over 250 scientific articles and developing novel approaches to animal health monitoring such as our Opti-Spot™ blood collection methodology.
• We are your partner in progressing research
• A global market leader in diagnostics solutions for animal health, water and dairy quality
• Over 6,500 global employees
• Over 400 scientists, pathologists and veterinarians on staff
• Over 60 locations worldwide
• Over 280 million invested in R&D in the last 5 years
IDEXX
Website: http://www.idexx.com
IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency, and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry, and testing for the quality and safety of water and milk. Headquartered in Maine, IDEXX employs more than 8,000 people and offers products to customers in over 175 countries.
Our purpose is to be a great company that creates exceptional long-term value for our customers, employees, and shareholders by enhancing the health and well-being of pets, people, and livestock.
For more information about IDEXX, visit: www.idexx.com
MSD Animal Health
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals®, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com/ or connect with us on LinkedIn and Twitter.
Consulting Partner
Stonehaven Consulting
Website: http://www.stonehaven-consulting.com
Stonehaven Consulting AG was founded in 2015 as a specialist Life Science management consultancy firm. Based in Switzerland, we provide international consulting services to all sectors in Life Sciences.
We are especially interested in assisting ambitious clients wishing to commercialise new technologies or leverage opportunities for growth. We do this by following a unique approach where we not only help our clients to develop the best possible strategy but partner with them to bring it to life – we are happy to share risks and opportunities. We are an experienced group of individuals with a long track record of successful operational and strategic management on many levels and for a number of multinational Animal Health companies as well as companies in Life Sciences.
Our founder, George Gunn has served as CEO for a number of companies and our other members of the team bring complementary skills and experience to our group. All of us have substantial experience and background in Animal Health – an industry we are very excited about.
Knowledge Partner
McKinsey & Company
Website: https://www.mckinsey.com
McKinsey & Company is one of the world's leading management consulting firms. For over 90 years, we have helped our clients achieve substantial, lasting improvements in their performance, including in the healthcare and animal health sectors. McKinsey's Animal Health service line is founded on our unrivaled breadth and depth of global, cross-functional experience. We bring to bear 360° insights across the entire animal health value chain, informed by our experience serving leaders in pharmaceuticals, distribution, agriculture, protein players, retailers, veterinary groups, and investors. Our global network of 50+ animal health practitioners works closely with teams at all levels of an organization to shape winning strategies, mobilize for change, build capabilities, and drive successful execution.
Senior Event Partners
Klifovet
Website: http://www.klifovet.com
KLIFOVET provides high quality services for the animal health and animal nutrition industry regarding the registration and marketing of all kind of veterinary products. We support ambitious young biotech and veterinary pharma companies on their way to the top by providing full business and product development management, regulatory affairs consultancy including dossier writing, compilation and submission, and full CRO services for safety and efficacy studies. We are proud on 18 years of experience, well organized logistics, a highly motivated team, and a comprehensive net of co-operators and skilled investigators throughout Europe, North America and the world. We handle large multinational projects as professionally as national ones, complying to national, EMA, EFSA or FDA standards.
Mars Petcare
Website: http://www.mars.com/global/brands/petcare
Mars Petcare is a growing segment of approximately 50 brands, made up of about 75,000 Associates in more than 55 countries who serve the nutrition and health needs of dogs, cats, horses, fish and birds every day.
Mars Petcare has been in operation for more than 75 years and now includes three of the top five pet food brands in the world - PEDIGREE®, WHISKAS® and ROYAL CANIN®. Mars Petcare is also home to the brands NUTRO®, GREENIES®, SHEBA®, CESAR®, IAMS® AND EUKANUBA®.
Mars Petcare is the world's biggest veterinary health group with hospitals such as BANFIELD®, BLUE PEARL®, PET PARTNERS®, and VCA® - making Mars the largest veterinary operation in the North America.
Connected Solutions, Mars Petcare's newest business division is the hotbed for future innovation with WISDOM PANEL® HEALTH patented genetic technology testing for dogs and the WHISTLE® dog tracker.
Nutreco NuFrontiers
Website: http://www.nutreconufrontiers.com
Nutreco is a global leader in animal nutrition and aquafeed. Our advanced nutritional solutions are at the origin of food for millions of consumers worldwide. Nutreco employs over 12,000 people in 35 countries with net sales of over € 6 billion. Our two global company brands Skretting (aquafeed) and Trouw Nutrition (animal nutrition) have sales in over 90 countries. Innovation sits at the very heart of Nutreco’s business and culture. Through our strategic innovation and investment division Nutreco NuFrontiers, we look to identify, develop and invest in next generation, sustainable products, models and services throughout the feed and food protein value chain.
NuFrontiers invests both in start-ups developing new technologies, ingredients or formulations, and joint-ventures and partnerships to create ‘moonshot projects’ that address major bottlenecks in the feed and food value chain.
For more information visit www.nutreco.com and www.nutreconufrontiers.com
Event Partners
Antelliq
Website: http://www.antelliq.com
Antelliq: intelligence connecting animals with people
Antelliq is the world’s leading animal intelligence group, providing world-class devices for animal identification and traceability. Our pioneering monitoring solutions deliver smart data products and services for the management and wellbeing of livestock, fish and pets.
For over 60 years we have been satisfying customer needs in over 100 countries, supported by 24 production sites, spanning five continents.
Antelliq has four regional innovation centres and many brands working collaboratively to address some of the world’s most pressing challenges:
- Supporting farmers with real-time actionable information: Through Allflex, SCR and our other livestock focused brands, our intelligence and monitoring helps farmers to manage herds and meet the world’s increasing demand for protein.
- Providing a deeper connection with pets: Through Sure Petcare, we provide pet owners with smart devices and data that give them a better understanding of their pets’ health needs and wellbeing, enriching relationships.
- Supporting conservation: Through Biomark, we help conservationists safeguard natural environments and wildlife.
Across Antelliq, our different brands provide the technology and intelligence that will be at the heart of overcoming these challenges. Antelliq is the embodiment of everything we stand for: intelligence connecting animals and people.
To discover more about our business, brands, innovation centres and where we operate, visit www.antelliq.com
Anterra Capital
Website: http://www.anterracapital.com
We are a specialist venture capital investor dedicated to financing the growth of companies operating in the food & agricultural sectors
We invest across the food supply chain in technology driven companies
We focus on companies headquartered in Europe or North America although we will consider companies in other geographies
At the time of our investment our companies are typically generating revenue and have great growth prospects
We invest up to USD 20m in equity per company taking a significant minority ownership position
We are active in the boards of portfolio companies working alongside management teams to build lasting value
As a sector specialist we pride ourselves on our ability to add value in ways that generalist investors can't even dream of
APHA Scientific
Website: http://www.aphascientific.com
Animal and Plant Health Agency (APHA) are an internationally recognised centre of scientific excellence providing a wide range of research and consultancy to the UK Government and commercial customers. We specialise in diseases of livestock and plants, diagnosis of disease and surveillance of new and emerging disease. APHA has achieved world reference laboratory status for a number of animal diseases.
To enhance its scientific activity APHA develops commercial products and services and makes them available to organisations globally. These are brought together under APHA Scientific to ensure the products and services are delivered effectively to customers.
Our products and services include:
- Biological reagents and test kits
- Proficiency testing (VETQAS)
- Wildlife management and radar detection
- Laboratory testing
- Vaccine development and testing
- Virus discovery
- Pathology and bio-imaging
- Bacterial identification and characterisation
- Veterinary research and development
- Access to Animal and Plant Health Agency intellectual property.
For more information about any of our services please contact
T: 03000 600001
E: [email protected]
www.aphascientific.com
Ceva
Website: http://www.ceva.co.uk
Ceva Santé Animale (Ceva) is one of the fastest growing top 10 veterinary healthcare companies. We research, develop and produce vaccines and pharmaceutical products for poultry, companion animals, livestock and swine.
Ceva has been directly present in China for over 15 years and is heavily invested through R&D partnerships and local production of vaccines.
Ceva Huadu, Beijing focuses on poultry vaccine production and the recently formed Ceva Ebvac, Hangzhou City, will drive the rapidly expanding swine vaccine business
Since 2011, Ceva has entered into a number of scientific cooperation agreements (South China Agricultural University (SCAU), University of Beijing) designed to share knowledge and ensure that the company’s international poultry and swine expertise can be applied to local conditions in China.
Globally, Ceva is one of the leading poultry healthcare suppliers having driven innovation in hatchery vaccination, to improve efficiency and performance. Ceva’s C.H.I.C.K programme was the first hatchery services programme to be independently approved by the international standards company, Bureau Veritas. Demonstrating the company’s commitment to help its customers to constantly enhance their productivity through different means of innovation.
In swine, the company has a balanced portfolio of vaccine and pharmaceutical products that are also supported by extensive veterinary and technical services programmes (Lung programme, Respinomics).
Our growth in China, reflects the entrepreneurial nature of Ceva, which is owned and managed by its senior management team. 40% of our growth has come from the more than 30 acquisitions and innumerable license agreements that we have made since 2000. As a result, we are always open to receiving innovation proposals to generate growth in China and beyond.
Clinvet
Website: http://www.clinvet.com
Clinvet is a GCP/GLP accredited Contract Research Organisation (CRO) established in 1999 and specialises in the conduct of laboratory and field-based efficacy, safety and metabolism trials for veterinary health products.
Since inception, Clinvet has conducted more than 1300 studies aiding in the discovery, development and registration of veterinary products worldwide.
Services offered by Clinvet
Laboratory in vitro and in vivo efficacy studies as well as safety and metabolism studies for animal medicine. We maintain an extensive bank of parasites (helminths and arthropods) originating from the US, EU and Africa for use in challenges on companion and production animals. Test animals frequently used include rats, rabbits, cats, dogs, goats, sheep, cattle and horses. We offer the following studies:
- Glass vial contact assay
- Artificial membrane feeding assay
- Proof of concept efficacy
- Dose determination and confirmation
- Parasite challenge efficacy
- Bioequivalence
- Pharmacokinetics
- Residue depletion
- Target animal safety
Clinical trial conduct as well as the following support services for animal clinical field and laboratory studies:
- Project management, monitoring and quality assurance
- Protocol, report writing and case report form (CRF) design
- Electronic database, design and validation (EDC/Paper)
- Data management, biostatistics and statistical programming
- Serological (IFA and ELISA) and molecular (qPCR and PCR) diagnostic testing
- Specialised molecular assay development
- Animal genetic profiling, parentage and mutation screening
- Genomic analysis of parasites
For more information, visit www.clinvet.com
The Department for International Trade (DIT)
Website: https://www.great.gov.uk/
The Department for International Trade (DIT) helps businesses export and grow into global markets. We also help overseas companies locate and grow in the UK - our services are provided in over 100 markets throughout the world.
We secure UK and global prosperity by promoting and financing international trade and investment, and championing free trade.
We are an international economic department, responsible for:
- bringing together policy, promotion and financial expertise to break down barriers to trade and investment, and help businesses succeed
- delivering a new trade policy framework for the UK as we leave the EU
- promoting British trade and investment across the world
- building the global appetite for British goods and services
DuPont
Website: http://www.dupont.com/
DUPONT INDUSTRIAL BIOSCIENCES
DuPont Industrial Biosciences, a business unit of DowDuPont Specialty Products Division, works with customers across a wide range of industries to make products and industrial processes more efficient and sustainable. Through a unique combination biotechnology, chemistry and material science capabilities, we advance market-driven, biobased solutions to meet the needs of a growing population, while protecting our environment for future generations. For updates about how DuPont Industrial Biosciences is helping customers deliver cost-effective products with superior performance and sustainability, follow @DuPontBiobased on Twitter or visit our website at biosciences.dupont.com.
DOWDUPONT SPECIALITY PRODUCTS DIVISION
DowDuPont Specialty Products, a division of DowDuPont (NYSE: DWDP), is a global innovation leader with highly differentiated materials, ingredients and capabilities that help transform industries and everyday life. DowDuPont Specialty Products includes five technology-driven businesses: Electronic Technologies, Industrial Biosciences, Nutrition & Health, Protective Solutions and Sustainable Solutions. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver real-world products and smart solutions across multiple high-value markets. DowDuPont intends to separate the Specialty Products division into an independent, publicly traded company.
www.dow-dupont.com.
Metabolon
Website: http://www.metabolon.com/
Metabolon, Inc. is the world’s leading health technology company advancing metabolomics for clinical and research uses. Its Precision Metabolomics™ is accelerating research and product development across the pharmaceutical, biotechnology, consumer products, and nutrition industries. The company was founded in 2000 and is based in Research Triangle Park, North Carolina.
OCR
Website: http://www.oncovet-clinical-research.com
OCR is a full-Vet CRO based in Lille-France, with a know-how on every steps of the clinical development and registration of a product for the pets market. OCR is specialized in clinical studies on severe diseases affecting dogs and cats: cancer, and others diseases in therapeutic areas like inflammation, cardiology, dermatology, antibiotic resistance, neurology. Along with a highly experienced team (clinical project leaders, RCA, data managers, biostatisticians, and veterinary specialist consultants), OCR built a European network of veterinary clinics with high level technical platform, including imaging (CT-scan, MRI, scintigraphy) and radiation therapy units and vet specialist strongly involved in clinical research. Our expertise in a nutshell: conception of the study with vet experts, determining pre-clinical and clinical development plans, conducting Proof-of-Concept studies, Pilot and Pivotal studies, site selection, laboratory identification and management, regulatory affairs, data management & biostatistics, VICH GCP clinical studies standards. Strong track record with the vet industry with pilot/pivotal studies, as well as with biotech/pharma through comparative medicine studies.
Paul Dick and Associates (PDA)
Website: http://pauldickassociates.com
Paul Dick & Associates Ltd. (PDA), founded in 2010, is an animal health consulting firm specializing in (1) the creation of strategic business and product life plans, (2) product development and regulatory affairs strategies, (3) the conduct of GCP studies, (4) the development of white papers to support marketing and sales, (5) business development and fundraising, (6) the acquisition and pitching of new technologies, actives and products, and, (7) various other supporting activities for product development and commercialization. The capabilities of Paul Dick & Associates Ltd. span the research, development, regulatory, and, commercialization continuum for animal pharmaceuticals, biologicals, vaccines, feed ingredients and feeds, and natural/ low risk health products. PDA is the recognized expert for these matters in Canada, as well as for other global markets.
Pet Flavors
Website: http://www.petflavors.com
Pet Flavors Inc. (PF, Inc.) is the world leading developer and manufacturer of quality flavor bases for both pharmaceutical drugs and nutritional supplements in the animal health industry. PF Inc. sells several types of flavor bases for use in formulating palatable canine, feline, and equine dosage forms that are sold on a worldwide basis. PF Inc's Artificial Powdered Beef Flavor; PC-0125 is sold to 9 of the top 10 largest animal health pharmaceutical companies in the world and has been successfully formulated in over 20 New Animal Drug Approvals (NADAs). Our company has over 30 years of experience with formulation and product development. With an active ingredient and our flavor bases we can create highly palatable chewable tablets, soft chews or granules. Our services include improving the palatability of an existing product, creating product line extensions or developing entirely new products. The goal of our company is to have all pharmaceutical and nutraceutical animal health companies develop new health products with flavoring in mind. By making medications and supplements taste and smell better, we can help pet owners develop a stress free process that ensures pets are obtaining the medication and nutrition they need to live longer, healthier lives.
Phibro Animal Health Corporation
Website: http://www.pahc.com
Phibro Animal Health Corporation is one of the leading animal health companies in the world and is dedicated to helping meet the growing demand for animal protein. We are a global diversified animal health and mineral nutrition company. We concentrate exclusively on animals for food production and are one of the few global companies offering a comprehensive range of animal health and mineral nutrition products. For nearly 40 years we have been committed to providing livestock producers with value-based products and solutions to help them maintain and enhance the health of their animals. We develop, manufacture and market a broad range of products for food animals including poultry, swine, beef and dairy cattle and aquaculture. Our products help prevent, control and treat diseases, enhance nutrition to help improve health and contribute to balanced mineral nutrition.
Triveritas
Website: http://www.triveritas.com
Triveritas is a veterinary CRO with local offices in Europe and North America providing assistance in the development and registration of biological and pharmaceutical products in Animal Health. With a global customer base, both start-up and Top 10 Animal Health companies count amongst returning customers. Regulatory Affairs services, from initial strategic advice to final submission of dossiers, are provided by a highly competent team, including biologicals and pharmaceuticals specialists, a toxicologist, CMC/Part II experts and Qualified Persons for Pharmacovigilance. An integrated approach to project management has lead to proven success in the approval of products at EMA, FDA, USDA and EPA. Clinical Studies, compliant to VICH GCP, are performed by fully trained, experienced Monitors, veterinarians, data managers and support scientists, together with collaborating Investigators and laboratories. Independent Quality Assurance auditors provide inspection services in VICH GCP/GLP/GMP.
ZENOAQ
Website: http://www.zenoaq.jp/english/index.html
ZENOAQ aims to create a shared and everlasting future for humans and animals. Amidst efforts to improve drug development, veterinary therapy and biotechnology, ZENOAQ strives to enhance the value of animals. The core activities in ZENOAQ are deeply connected with our customers, which in turn, affects their animals in many different ways. These connections form a network that is not just limited to Japan, but is something that will also reach across international borders, creating mutual benefit for both humans and animals in the future.
ViVet
Website: http://www.vivet.org.uk
ViVet: The Network for Veterinary Innovation
ViVet is a wide-ranging programme to support veterinary professionals to engage with innovation and to encourage innovators to engage with the veterinary professions when launching new products or services. In doing so it seeks to put veterinary professionals at the centre of innovation in the animal health sector.
The programme showcases new technologies and businesses, and provides practical advice on launching new products and services, through online resources and events. Under the programme regulatory advice and guidance will be made available to help veterinary professionals working at the forefront of innovation or those from outside the profession seeking to bring new products or services to the veterinary or animal health market.
ViVet is driven by the mission of ‘enabling creative veterinary solutions for the good of animal health and welfare’. The programme is managed by the Royal College of Veterinary Surgeons (RCVS) and was inspired by the Vet Futures research initiative.
Vetoquinol
Website: http://www.vetoquinol.co.uk
Founded in 1933, Vetoquinol is the 9th largest veterinary pharmaceutical business, committed to the protection and well-being of both animals and people.
Virbac
Website: https://uk.virbac.com/
Founded in 1968 by a French veterinarian, Virbac is an independent pharmaceutical laboratory dedicated to animal health, since its beginning. Currently the world’s 7th largest animal health company, Virbac sells products in more than 100 countries, offering a comprehensive and practical range of products and services covering the majority of species and pathologies. Virbac innovation, based on both technological advances and listening to its customers, relies on reactive production facilities which meet the highest international quality standards. For nearly fifty years, these features have allowed the company to build a personalized relationship with veterinarians and farmers around the world.
Media Partners
Animal Pharm
Website: https://animalpharm.agribusinessintelligence.informa.com
We have been providing animal health professionals worldwide with news, analysis and insight for over 30 years, and cover the food producing animal and companion animal sectors. With extensive information on animal health products including antiparasitics, vaccines, pharmaceuticals, feed, feed additives and equipment.
Features include:
- Analysis of business and company news
- Reporting on key players in the industry
- Market developments and trends
- Analysis of the latest global regulatory changes
- News on product research and development
- Expert opinion and analysis
feed&food
Website: http://www.feedfood.com.br
A Editora Ciasulli chega ao mercado com uma expertise de mais de 45 anos em jornalismo do agronegócio e em meio aos dez anos de edição da publicação feed&food, porta-voz da agroindústria da cadeia de proteína animal e preocupada com o abastecimento de alimentos para as 9 bilhões de bocas em 2050.
A revista mensal, somada ao portal de notícias (www.feedfood.com.br) e suas demais ferramentas, como aplicativos para Android e iOS (www.revistafeedfood.com.br), e projeto paralelos, tem como objetivo a atualização de conhecimento para todos os profissionais ligados à cadeia de proteína de origem animal, seja na área de avicultura (corte e postura), suinocultura, bovinocultura (corte e leite), aquacultura e todo o segmento food; servindo como ponte de discussão e entrosamento entre entidades, governo e iniciativa privada.
Missão: Disseminar informações que promovam conhecimento focado em segurança alimentar.
Visão: Informar e inspirar leitores a transformarem o conhecimento em ações práticas em prol das gerações de hoje e futuras.
Valores: Ética, transparência, otimismo, foco, inovação e empreendedorismo.
Veterinary Practice News
Website: http://www.veterinarypracticenews.com
Find out more about us on our website.
VetRecord
Website: https://veterinaryrecord.bmj.com/
Vet Record is the official journal of the British Veterinary Association (BVA) and has been published weekly since 1888. It contains news, comment, letters and clinical research papers on a wide range of veterinary topics. Its classified advertisement section includes an extensive list of veterinary and veterinary-related jobs.
Become a Sponsor
Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.